Table 2.
Baseline and Postprocedural Predictors of 1‐Year Gait Speed
| Univariable | Multivariable | ||||
|---|---|---|---|---|---|
|
β Estimate (95% CI) |
P Value |
β Estimate (95% CI) |
P Value | ||
| Clinical factors (baseline) | |||||
| Gait speed at baseline (per 0.1 m/s increase) | 0.49 (0.41 to 0.56) | <0.0001 | 0.38 (0.30 to 0.46) | <0.0001 | |
| Max grip strength (per 1 kg increase) | 0.09 (0.07 to 0.11) | <0.0001 | |||
| Female sex | −1.47 (−1.90 to −1.04) | <0.0001 | −0.51 (−0.93 to −0.09) | 0.02 | |
| STS score (per increase of 1) | −0.17 (−0.23 to −0.12) | <0.0001 | −0.09 (−0.14 to −0.04) | 0.0007 | |
| Katz ADLs (per 1 increase) | 0.78 (0.49 to 1.06) | <0.0001 | 0.28 (0.02 to 0.54) | 0.03 | |
| NYHA III/IV at baseline | −1.18 (−1.65 to −0.71) | <0.0001 | −0.49 (−0.90 to −0.07) | 0.02 | |
| Orthopedic disease | −1.47 (−2.14 to −0.81) | <0.0001 | −0.85 (−1.45 to −0.25) | 0.005 | |
| Age (per 1‐y increase) | −0.06 (−0.09 to −0.03) | <0.0001 | |||
| History of coronary disease | 0.85 (0.35 to 1.35) | 0.001 | 0.50 (0.05 to 0.95) | 0.03 | |
| History of COPD | −0.77 (−1.25 to −0.28) | 0.002 | −0.40 (−0.82 to 0.02) | 0.06 | |
| Mini‐COG (per 1‐point increase) | 0.21 (0.05 to 0.37) | 0.01 | 0.16 (0.01 to 0.30) | 0.03 | |
| NYHA III/IV at 30 d | −0.90 (−1.70 to −0.09) | 0.03 | |||
| New onset Afib between the procedure and 1 y | −0.89 (−1.83 to 0.05) | 0.06 | |||
| History of Afib or flutter | −0.44 (−0.91 to 0.03) | 0.06 | |||
| Stroke (any) between procedure and 1 y | −0.92 (−1.99 to 0.14) | 0.09 | |||
| BMI (per increase of 1) | −0.02 (−0.06 to 0.01) | 0.21 | |||
| Bleeding (life‐threatening, disabling, or major) between the procedure and 1 y | −0.32 (−0.97 to 0.34) | 0.35 | |||
| Hospitalization for valve‐related symptoms or worsening CHF between the procedure and 1 y | −0.36 (−1.16 to 0.44) | 0.37 | |||
| Moderate or severe mitral regurgitation at baseline | −0.29 (−1.06 to 0.48) | 0.46 | |||
| History of PVD | 0.17 (−0.31 to 0.66) | 0.49 | |||
| History of CVA | −0.25 (−0.97 to 0.47) | 0.49 | |||
| Major vascular complication between the procedure and 1 y | −0.32 (−1.37 to 0.73) | 0.55 | |||
| EF at 30 d (per 5% increase in EF) | −0.02 (−0.13 to 0.09) | 0.71 | |||
| Diabetes mellitus (medically treated) | −0.06 (−0.54 to 0.41) | 0.79 | |||
| New pacemaker between the procedure and 1 y | 0.06 (−0.41 to 0.54) | 0.80 | |||
| Immunosuppressive therapy | −0.08 (−0.88 to 0.72) | 0.85 | |||
| Mean pressure gradient (MPG) on 30‐d echo (per 5‐mm Hg increase) | −0.02 (−0.21 to 0.17) | 0.85 | |||
| Mean pressure gradient (MPG) at baseline (per 5 mm Hg increase) | 0.01 (−0.08 to 0.09) | 0.89 | |||
| EF at baseline (per 5% increase in EF) | 0.00 (−0.10 to 0.11) | 0.96 | |||
| Moderate or severe aortic regurgitation on 30‐d echo | 0.02 (−1.28 to 1.32) | 0.98 | |||
Multivariable model R 2=0.29. Afib indicates atrial fibrillation; BMI, body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; EF, ejection fraction; Katz ADLs, Katz Index Activities of Daily Living Score; Mini‐COG, Mini‐Cognitive Assessment for Dementia Score; MPG, mean pressure gradient; NYHA, New York Heart Association; PVD, peripheral vascular disease; and STS, Society of Thoracic Surgeons score.